Memantine is an NMDA receptor antagonist used to treat moderate to severe dementia in Alzheimer's. Identification · Pharmacology · Interactions · Products

Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD).

Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD).

UNLABELLED: We review preclinical and clinical evidences strongly suggesting that memantine, an old drug currently approved for Alzheimer's dementia, is an ...

Memantine (Namenda) is prescribed as a treatment for moderate to severe Alzheimer's Disease. Memantine functions by blocking the NMDA receptor, but the key ...

Abstract. Memantine is reported to improve symptoms in moderate cases of Alzheimer's disease and Parkinson's disease, but is also known to trigger psychosis ...

Memantine. Also known as: Product containing memantine (medicinal product) / Memantine (substance). Drug Trials. Drug, Drug Name, Drug Description. Drug, Drug ...

Alzheimer's Disease (AD) Completed Phase 3 Trials for Memantine (DB01043) ; NCT00235716. A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's ...

Alzheimer's Disease Completed Phase 4 Trials for Memantine (DB01043) ; NCT00305903. Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients ...

Memantine completed Phase 3 trials for dementia of the Alzheimer's type treatment. Back to Memantine. Stay up-to-date with the latest from DrugBank!